Zomedica reports 2022 revenue of $18.9M, up 361% YoY; net loss narrows to $17.0M

Zomedica Corp.

Revenue $18.9M, up 361% from $4.1M in 2021; 72% gross margin.
Net loss $17.0M vs $18.4M in 2021; improvement of $1.4M (8%).
Cash, equivalents and securities $156M at Dec 31, 2022; no SVB/Signature exposure.
PulseVet small-animal device sales grew 405% in 2022; VetGuardian launched; TRUVIEW expected Q2 2023.
Acquisitions of Assisi and Revo Squared contributed; evaluating further M&A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.